VivoSeq
Metabolic & Endocrine

Thyroid Nodule

8

Pipeline Programs

3

Active Trials

3

Companies Involved

Thyroid Nodule is an early-stage landscape with 8 programs across 3 companies. The most active players are Astellas, Roche, Xintian Pharmaceutical. 2 therapies are approved with 2 more in late-stage development.

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

50/100

Attrition Rate

29/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Modality Breakdown

90%

Small molecule

9 of 10 classified programs — the dominant modality here.

10%ALL OTHERSRadiopharmaceutical110%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.

Trial Status

7

clinical trials

Completed2 · 29%
Recruiting2 · 29%
Terminated1 · 14%
Not yet recruiting1 · 14%
Withdrawn1 · 14%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)